Irritable Bowel Syndrome (IBS) Therapeutics Market Report

Global and Region Irritable Bowel Syndrome (IBS) Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：199
  • REPORT CODE：GMM980293
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.

    The report details the trend, potential and market size of Irritable Bowel Syndrome (IBS) Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Irritable Bowel Syndrome (IBS) Therapeuticsmarket, defines the market attractiveness level of Irritable Bowel Syndrome (IBS) Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Irritable Bowel Syndrome (IBS) Therapeutics industry, describes the types of Irritable Bowel Syndrome (IBS) Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Irritable Bowel Syndrome (IBS) Therapeutics market and the development prospects and opportunities of Irritable Bowel Syndrome (IBS) Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Irritable Bowel Syndrome (IBS) Therapeutics market in Chapter 13.

    By Player:

    • Ardelyx

    • Sucampo Pharmaceuticals

    • Abbott Laboratories

    • Synergy Pharmaceuticals

    • Astellas Pharma

    • GlaxoSmithKline

    • Novartis

    • Ironwood Pharmaceuticals

    • Valeant Pharmaceuticals International

    By Type:

    • Blautix (Strain)

    • Bekinda (IBS-D)

    • SYN-010

    • Tenapanor

    By End-User:

    • Hospital

    • Research

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Irritable Bowel Syndrome (IBS) Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Irritable Bowel Syndrome (IBS) Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Irritable Bowel Syndrome (IBS) Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.2 United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.4 China Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.5 Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.6 India Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    9 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Blautix (Strain) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Bekinda (IBS-D) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global SYN-010 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Tenapanor Consumption and Growth Rate (2017-2022)

    • 9.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Research Consumption and Growth Rate (2017-2022)

    10 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Blautix (Strain) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Bekinda (IBS-D) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global SYN-010 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Tenapanor Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Research Consumption Forecast and Growth Rate (2022-2028)

    11 Global Irritable Bowel Syndrome (IBS) Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Competitive Analysis

    • 14.1 Ardelyx

      • 14.1.1 Ardelyx Company Details

      • 14.1.2 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.2 Sucampo Pharmaceuticals

      • 14.2.1 Sucampo Pharmaceuticals Company Details

      • 14.2.2 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.3 Abbott Laboratories

      • 14.3.1 Abbott Laboratories Company Details

      • 14.3.2 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.4 Synergy Pharmaceuticals

      • 14.4.1 Synergy Pharmaceuticals Company Details

      • 14.4.2 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.5 Astellas Pharma

      • 14.5.1 Astellas Pharma Company Details

      • 14.5.2 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.6 GlaxoSmithKline

      • 14.6.1 GlaxoSmithKline Company Details

      • 14.6.2 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.7 Novartis

      • 14.7.1 Novartis Company Details

      • 14.7.2 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.8 Ironwood Pharmaceuticals

      • 14.8.1 Ironwood Pharmaceuticals Company Details

      • 14.8.2 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • 14.9 Valeant Pharmaceuticals International

      • 14.9.1 Valeant Pharmaceuticals International Company Details

      • 14.9.2 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Irritable Bowel Syndrome (IBS) Therapeutics

    • Figure Irritable Bowel Syndrome (IBS) Therapeutics Picture

    • Table Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Blautix (Strain) Consumption and Growth Rate (2017-2022)

    • Figure Global Bekinda (IBS-D) Consumption and Growth Rate (2017-2022)

    • Figure Global SYN-010 Consumption and Growth Rate (2017-2022)

    • Figure Global Tenapanor Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Research Consumption and Growth Rate (2017-2022)

    • Figure Global Blautix (Strain) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Bekinda (IBS-D) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global SYN-010 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tenapanor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Research Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Irritable Bowel Syndrome (IBS) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Irritable Bowel Syndrome (IBS) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Ardelyx (Foundation Year, Company Profile and etc.)

    • Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Sucampo Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Abbott Laboratories (Foundation Year, Company Profile and etc.)

    • Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Synergy Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Astellas Pharma (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Ironwood Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product and Service

    • Table Valeant Pharmaceuticals International (Foundation Year, Company Profile and etc.)

    • Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US